Consensus Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
4.15 ^USD	-4.60%		+8.36%	-3.26%

May. 08	BofA Securities Starts Sutro Biopharma With Buy Rating	MT
Apr. 30	Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	CI

Evolution of the average Target Price on Sutro Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

575ac180ac811e.zRy8HTJHX2Qg7kGShC0h0z1KSofzMWCPO1d_LvZnCHc._G6OUGhqbx5pqxHq_X57kHV9evbABAHAWDQISJg9PEaPbvhsYBBoF2utKg~ccb3854bc0454279dea63145958a9b13

Analyst Recommendations on Sutro Biopharma, Inc.

BofA Securities Starts Sutro Biopharma With Buy Rating	May. 08	MT
Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	Apr. 03	MT
Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	Apr. 03	MT
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	Mar. 26	MT
Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	Nov. 15	MT
Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target	23-10-06	MT
Wedbush Cuts Sutro Biopharma's PT to $12 From $20, Pushes Back Estimated Launch of STRO-002, Adjusts Capital Raise Assumptions; Keeps Outperform Rating	23-08-11	MT
JMP Securities Adjusts Price Target on Sutro Biopharma to $17 From $20, Maintains Market Outperform Rating	23-04-03	MT
HC Wainwright Adjusts Price Target on Sutro Biopharma to $16 From $20, Keeps Buy Rating	23-03-31	MT
Truist Securities Adjusts Sutro Biopharma's Price Target to $25 From $21, Keeps Buy Rating	23-01-13	MT
Piper Sandler Adjusts Price Target on Sutro Biopharma to $18 From $16, Maintains Overweight Rating	23-01-10	MT
HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating	22-11-09	MT
Truist Securities Adjusts Sutro Biopharma Price Target to $21 From $37, Maintains Buy Rating	22-08-23	MT
Berenberg Bank Adjusts Sutro Biopharma's Price Target to $26 From $30, Maintains Buy Rating	22-08-09	MT
Piper Sandler Reduces Sutro Biopharma's Price Target to $14 From $29, Reiterates Overweight Rating	22-05-23	MT
Piper Sandler Adjusts Sutro Biopharma Price Target to $14 From $29, Maintains Overweight Rating	22-05-23	MT
Wedbush Cuts Sutro Biopharma's Price Target to $20 From $30, Citing Launch Timelines, Cost of Capital; Outperform Rating Kept	22-05-10	MT
JMP Securities Adjusts Sutro Biopharma's Price Target to $20 From $28, Maintains Market Outperform Rating	22-03-07	MT
Wedbush Cuts Sutro Biopharma's Price Target to $30 From $37, Citing Adjusted Timelines for STRO-001, -002; Outperform Rating Kept	22-01-06	MT
Sutro Early-Stage Ovarian Cancer Study Shows 33% Objective Response Rate -- Shares Drop in Pre-Market Trading	22-01-06	MT
Sutro Says Interim Data From STRO-002 Early-Stage Study Shows 33% Objective Response Rate -- Shares Drop After-Hours	22-01-05	MT
Berenberg Bank Initiates Coverage on Sutro Biopharma With Buy Rating, $30 Price Target	21-11-17	MT
SUTRO BIOPHARMA : Wedbush Adjusts Sutro Biopharma's Price Target to $37 From $34, Keeps Outperform Rating	21-08-10	MT
SUTRO BIOPHARMA : HC Wainwright Starts Sutro Biopharma at Buy With $35 Price Target	21-06-18	MT
SUTRO BIOPHARMA : Wedbush Adjusts Sutro Biopharma's Price Target to $34 From $33, Keeps Outperform Rating	21-03-19	MT